Sector News

Advent, near deal to buy Sanofi's Zentiva, lays out big goals for generics business

April 18, 2018
Life sciences

The sources were right: Only one day after numerous media reports stated Sanofi was nearing a deal with Advent International to sell its copycat drug unit Zentiva, the companies acknowledged that they are in exclusive negotiations. And Advent said it has big plans for the European generics business.

In a proposed €1.9 billion ($2.35 billion) deal, Sanofi would offload its Zentiva unit to buyout firm Advent International. The private equity outfit said it will invest in the company and create a “new, independent European generics leader,” according to a release.

The sides hope to finish the deal by the end of the year, noting that it’s contingent on finishing definitive agreements and regulatory approvals.

While Sanofi CEO Olivier Brandicourt said in a statement that Zentiva has “demonstrated its potential for growth,” he said the best path forward for the business is with Advent. Brandicourt has been working to reshape Sanofi for years after coming on board in 2015.

Advent has done a series of deals in the drug business, including specialty pharma buyouts in Latin America and generics deals on both sides of the Atlantic. Back in 2003, it took Terapia, Romania’s largest independent generics maker, from public to private and invested in Argentina’s Fada Pharma prior to that. It has since exited both companies via sale, with Terapia going to Ranbaxy Labs in 2006.

“We have long been attracted to the generics pharmaceutical sector as it enables more people to access high quality treatments by lowering their cost. We believe that Zentiva is a great platform, full of talented people, who we can invest behind to build a new, independent, European generics leader,” Advent healthcare executive Tom Allen said in a Tuesday statement.

For Sanofi’s part, the French drugmaker started talked about selling Zentiva back in 2015, but Brandicourt made other moves first after taking the helm. He offloaded Sanofi’s animal health business Merial in 2016 through an asset swap with Boehringer Ingelheim, getting BI’s consumer health assets in return.

Part of the refocusing effort also includes a pipeline and rare disease expansion. Sanofi purchased nanobody biotech Ablynx this year for $4.8 billion and hemophilia-focused Bioverativ for $11.6 billion. Brandicourt said the acquisitions “dramatically reshape our portfolio in specialty care” and boost the company’s R&D presence.

The Zentiva auction process attracted buyers including Indian and Chinese drugmakers and other private equity firms, according to reports. Along the way, India’s Torrent and PE firm Nordic Capital reportedly bowed out due to price.

Zentiva operates in 50 countries and sells drugs in disease areas including cardiovascular, central nervous system, gastrointestinal and metabolic disorders. It brought in €760 million last year, a 4.9% decrease from 2016.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach